Professor of Medicine, University of Ottawa
Division of Medical Oncology
Dr. Stewart returned to Ottawa from the University of Texas MD Anderson Cancer Center (Houston, TX) in 2011 to assume the position of Head of the Division of Medical Oncology at The Ottawa Hospital and the University of Ottawa. He received his MD degree from Queen’s University, Kingston, followed by training in Internal Medicine at McGill University and in medical oncology in the Department of Developmental Therapeutics at the UT MD Anderson Cancer Center. He first moved from MD Anderson to the University of Ottawa in 1980, and served as Chief of Medical Oncology at the Ottawa Civic Hospital from 1989 to 1999. He returned to the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center from 2003 to 2011 where he served as Chief of the Section of Experimental Therapeutics (2003-2005), Chair Ad Interim (2005), Deputy Chair (2006-2009), and Director of Translational Research (2009-2011). He was also the Principle Investigator of MD Anderson’ phase II N01 contract with the National Cancer Institute, and was the clinical leader of a number of other federally-funded translational research projects.
His primary focus clinically is therapy of advanced lung cancer. He has published more than 310 peer-reviewed papers, and edited the text Lung Cancer: Prevention, Management and Emerging Therapies published in 2010. His primary area of research interest is personalization of therapy using tools that include phase I and II clinical trials, studies of plasma pharmacokinetics and tumor and normal tissue uptake of chemotherapy agents, resistance mechanisms, resistance modulation, and host single nucleotide polymorphisms and tumor biomarkers that correlate with treatment outcome and prognosis. He also has a major interest in and concern for issues impeding cancer clinical research, with publications that have included (among others) Cancer: the road to Amiens (Journal of Clinical Oncology 27(3):328-33, 1/2009), Equipoise lost: ethics, costs and the regulation of cancer clinical research (Journal of Clinical Oncology 28(17):2925-35, 2010), Fool’s gold, lost treasures and the randomized clinical trial (BMC Cancer 2013 Apr;13(1):193),and Redefining cancer: a new paradigm for better and faster treatment innovation. J Popul Ther Clin Pharmacol 2014 Feb 23; 21(1):e56-e65).
Lung and other Thoracic Cancers
Education and Training
Doctorate of Medicine, Queen's University
Internal Medicine, McGill University
Medical Oncology, UT MD Anderson Cancer Center